Stupp to our level.

The level of low-intensity frequency, that is. Dr. Roger Stupp himself reported (via presentation no: LBA-6), for the first time, detailed quality of life (QoL) data from his landmark EF-14 trial. You remember, the one that established tumor-treating fields (TTF) in combo with temozolomide as standard of care for maintenance therapy in the treatment of glioblastoma multiforme (GBM). What’s that...? You’re not seeing GBM follow-ups regularly wearing TTF caps? That’s probably due to pervasive concerns about the detrimental impact on QoL of wearing the device for most hours of the day. On the contrary, outcomes across several QoL parameters showed all (read: global health, emotional, functional, etc) are significantly improved with TTF except one--itchy skin. At turns out, what’s really detrimental to quality living is a tumor growth-induced neurocognitive decline.